Key Takeaways
- Revenue surged 50% in H1, but lithium prices are the story: H1 revenue hit ₹300 cr, putting the company on track for ₹650-700 cr for FY23, yet peak lithium prices compressed percentage margins and briefly dented inorganic volumes.
- Lithium pass-through protected absolute EBITDA: Management secured back-to-back contracts and passed on a historic 4-5x lithium price increase to customers, preserving absolute earnings even as percentage margins dipped.
- The lithium salt pivot is accelerating: Neogen prioritised the 400 MT lithium salt derivatives plant over the electrolyte plant, citing immediate international demand; commissioning is expected by Q4 FY23 with trials in Q1 FY24.
- Pharma demand hit a soft patch, now mending: Abnormally low demand for some large-volume pharma molecules, attributed to a post-COVID inventory correction, dragged on volumes for two quarters but is now improving sequentially.
- What to watch next quarter: Whether lithium prices hold at their new "stable" level, the pace of pharma demand normalisation, and final customer confirmations that unlock the larger lithium-ion battery materials CapEx decision.
Lithium Strategy & Battery Materials
- Salt plant first, electrolyte later: Management prioritised the lithium electrolyte salts and additives plant at Dahej SEZ over the electrolyte plant because international electrolyte makers have immediate demand, while Indian electrolyte consumption is still taking time to start.
- 400 MT salt derivatives plant: Commissioning is expected by Q4 FY23, with trial production starting by Q1 FY24; this capacity alone carries a ~₹100 cr revenue potential at peak utilisation.
- Electrolyte plant timeline: Now expected by Q1 or Q2 of FY24, corrected from an earlier FY23 target; the plant will serve only the Indian market, as electrolyte is a local business.
- Capacity strategy is sequenced: Management will first sell salts internationally, gather demand feedback, then plan a larger salt capacity that serves both India and international markets; electrolyte capacity will be sized based on India demand alone.
- Sodium-ion R&D has begun: The R&D team is exploring sodium-ion chemistry to serve Indian companies that have announced sodium plans, using the same facilities with some modifications.
- Customer engagement is active: Neogen is working with more than 15 international customers and has received positive feedback on lithium electrolyte salts and additives; sample testing and approval processes are underway.
- Technology partnerships: Several global technology providers have shown keen interest in partnering with or sharing technology with Neogen.
- Larger CapEx decision pending: Any large CapEx for lithium-ion battery materials depends on final customer confirmations, expected by March or before; a decision could come anytime between now and March.
Dr. Harin Kanani: "In terms of lithium salts, international customers, who are making electrolyte or who are making other electrolytes, the requirement is today because it is being consumed even today. ... Whereas, for electrolyte, the Indian customers are still taking time to start consuming the electrolytes."
Margin & Cost Structure
- Lithium prices compressed percentage margins: The single biggest impact on EBITDA percentage margins was higher lithium prices, which inflated both revenue and raw material cost while preserving absolute EBITDA.
- Lithium price outlook: Management believes lithium prices have peaked and are now at a new stable price for at least the next one to two years, with a ~10% correction already seen from the Q2 peak.
- Sourcing advantage: Neogen's ability to source lithium at competitive rates versus competitors, who sometimes cannot get enough lithium, allowed the company to pass on increases and even find new customers when existing ones resisted.
- Employee cost elevated but temporary: Employee cost at ~8% of revenue is historically high because peak headcount was reached before peak turnover from Dahej and other sites; this is expected to moderate as quarterly utilisation reaches ₹175-200 cr.
- Tax rate to improve: The H1 tax rate of ~29% is conservative because Dahej operations are still ramping up; as Dahej contributes more, the overall rate should improve to at least 25-26% or below.
- Working capital strained in H1: Negative cash flow from operations of ₹93 cr was driven by the ramp-up from ~₹80 cr to ₹150 cr+ quarterly revenue, requiring higher debtors and stock, plus abnormally low pharma demand causing inventory build-up.
- H2 working capital improvement expected: Inventory levels should be lower by March-end, and overall H2 will be better than H1 from a working capital perspective.
Dr. Harin Kanani: "I am very happy to say that our team worked really well with the right procurement at the right time; getting into back-to-back contracts, where we ensured that in spite of a historical 4-5 times increase in lithium prices, still we were able to pass on all the lithium prices to our customers while basically protecting our absolute EBITDA margin."
Demand Environment
- Organic chemicals grew steadily: H1 FY23 saw 19% growth; Q2 FY23 grew 9% YoY and added ~₹10 cr (~10%) sequentially, driven by volume growth both YoY and QoQ. Organic revenue was up by 10% at Rs. 10 crore as compared to previous quarter.
- Inorganic chemicals surged on realisations: H1 FY23 grew 176%, largely driven by realisation gains; Q2 FY23 jumped 122% YoY, though volumes dipped slightly QoQ due to customer resistance to peak lithium prices.
- Lithium price resistance fading: Some customer volumes decreased in Q2 versus Q1 due to resistance to high prices and pre-booking in Q1, but most customers have now accepted the new price.
- Pharma demand hit by inventory correction: Some large-volume pharma molecules, including the largest at 10-15% of revenue, saw abnormally low demand for two quarters due to supply chain inventory built up during COVID; demand is now improving, with Q2 better than Q1.
- Pharma normalisation timeline: Full normalisation is expected between six months and a year from now; the typical inventory correction cycle takes one to one-and-a-half years, and six months have already passed.
- Agrochemical demand steady: No decrease seen in agrochemical demand.
- Chinese competition intensifying: With slowing demand and overcapacity, Chinese competitors are becoming more aggressive on pricing in both pharma and agro, sometimes selling at historically low prices that do not even cover raw material cost; this is more pronounced in non-regulated pharma and agro due to easier customer switching.
- Facility repurposing during pharma slowdown: Neogen will use the facility to make other intermediates in the current and next quarter, which will help increase organic revenue.
Dr. Harin Kanani: "Sometimes we have seen prices from China, which is really difficult to believe, are historically low. Sometimes, we even believe that this is a very good case for anti-dumping, because they are basically selling at a very, very low price, which even raw material does not make sense."
Customer & Product Mix Shift
- CSM share rising: CSM revenue increased from 10% to 15% in H1 FY23, moving toward the 20% target by FY24; four to five molecules moved from pilot to first commercial production across Agro, Flavour & Fragrance, and Specialty Chemical/Engineering industries.
- Five new customers added: New customers in Europe and Japan span Agrochemical, Flavours & Fragrance, and Engineering segments; projects moved from pilot to first commercial operation.
- Inquiry pipeline building: Inquiries are rising across Europe and Japan, mostly with innovators or global leaders in flavour & fragrances (Europe) and agrochemicals (Japan and Europe); potential molecule sizes are ₹15-50 cr each, likely representing long-term demand.
- Six advanced intermediates progressing: Six own advanced intermediates, targeted at Pharma and Agro end-use, have completed pilots and/or first commercial run, with ~₹150 cr revenue potential that will start contributing in H2 and reach peak by FY25.
- Organolithium capability added: Neogen extended capabilities from Grignard chemistry to Organolithium chemistry at commercial scale.
- Dahej site ready for customer engagement: Management has started approaching bigger agrochemical companies and seen good response in initial presentations; potential projects are being identified.
- Product mix shifting to high-value: Production is shifting to high-value customised products with better demand visibility; these are complex, value-accretive products leading to customer stickiness.
Capacity & CapEx
- Organic chemical capacity expansion: Expected to be completed by Q1 or maximum Q2 of next financial year.
- Dahej utilisation ramping up: Mahape/Karakhadi utilisation is ~80-85%, while Dahej is at ~60-65%, with some materials made but not yet sold.
- FY25/FY26 additional revenue potential: ₹250-300 cr at full utilisation, from three sources: additional lithium capacity (~₹50 cr), 60KL additional reactor volumes (~₹100 cr), and lithium-ion battery material salts (~₹100 cr).
- CapEx funding mix: Plan is a mix of already-raised equity, internal accruals, and additional debt; the debt-equity ratio target is to remain around 1:1, with a maximum of 1.25 for a short period, otherwise below 1:1.
- Electrolyte plant sizing: Capacity will be determined by Neogen's market share in the Indian electrolyte market, with internal projections covering a minimum and maximum case.
- Inventory expected to improve: As new capacity gets added and inventories are liquidated or converted into sales in H2, inventory levels should decline.
- FY24 working capital target: Goal to reach ~110-120 days of stock inventory levels on a net sales basis by FY24, then gradually improve as new molecules come from more dedicated facilities in FY25 and FY26.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 revenue | ₹650-700 cr (up from earlier ₹600 cr target, depending on lithium) | FY23 |
| FY23 EBITDA | ₹100-110 cr | FY23 |
| FY24 revenue | ₹700-725 cr | FY24 |
| Lithium salt derivatives plant commissioning | 400 MT plant ready; trial production begins | Commissioning by Q4 FY23; trials by Q1 FY24 |
| Electrolyte plant readiness | Plant ready | Q1 or Q2 FY24 |
| Organic chemical capacity completion | Additional capacity online | Q1 or maximum Q2 FY24 |
| CSM revenue share | 20% of ~₹750 cr revenue | FY24 |
| FY25/FY26 additional revenue at full utilisation | ₹250-300 cr from lithium capacity, reactor volumes, and battery material salts | FY25/FY26 |
| Advanced intermediates revenue potential | ~₹150 cr from six molecules, contributing from H2 | Peak by FY25 |
| Tax rate improvement | At least 25-26% or below | By year-end FY23 |
| Pharma demand normalisation | Return to normal demand levels | Six months to one year from Q2 FY23 |
| Working capital improvement | Inventory levels lower than September 2022 | By March 2023 |
| Working capital days target | ~110-120 days of stock inventory on net sales | FY24 |
| Lithium-ion battery materials CapEx decision | Based on final customer confirmations | Anytime between now and March 2023 |
| Debt-equity ratio | Around 1:1, max 1.25 for short period, otherwise below 1:1 | Ongoing |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹148.1 cr, +31% YoY |
| Organic chemicals revenue | ₹99 cr, +9% YoY |
| Inorganic chemicals revenue | ₹49 cr, +122% YoY (from ₹22 cr in Q2 FY22) |
| Domestic:Export mix | 50:50 |
| EBITDA | ₹24.3 cr, +18% YoY |
| PAT | ₹9.9 cr |
| H1 FY23 revenue | ₹296 cr, +50% YoY |
| H1 FY23 EBITDA | ₹48.9 cr, +35% YoY |
| H1 FY23 PAT | ₹21 cr, +13% YoY |
| FY23 full-year revenue guidance | ₹650-700 cr, depending on lithium price behaviour in H2 |
| FY23 full-year EBITDA target | ₹100-110 cr |
| FY24 revenue guidance | ₹700-725 cr |
| Additional revenue by FY25/FY26 at full utilisation | ₹250-300 cr |
| Mahape and Karakhadi utilisation | 80-85% |
| Dahej site utilisation | 60-65% |
| CSM revenue share | 15% in H1 FY23, target 20% by FY24 |
| R&D team size | 60 members |
| H1 FY23 operating cash flow | negative ₹93 cr |
| Net debt | ~₹250 cr |
| Employee cost as a percentage of revenue | ~8%, historically highest level |
| H1 FY23 effective tax rate | ~29% |
| New customers added in the quarter | 5, across Europe and Japan, combined revenue potential of more than ₹200 cr |
| Advanced intermediates revenue potential | ~₹150 cr, pilots and/or first commercial run completed |
| Lithium salt derivatives plant peak revenue potential | ~₹100 cr at full utilisation |
| Small electrolyte trial capacity | 200 kg per month |